Infliximab Concentrations during Induction Are Predictive for Endoscopic Remission in Pediatric Patients with Inflammatory Bowel Disease under Combination Therapy

To study infliximab (IFX) pharmacokinetics in children with inflammatory bowel disease (IBD) during induction therapy to predict outcome and explore if other covariates influenced outcome. All children with IBD starting IFX therapy (5 mg/kg at weeks 0, 2, 6, and 12) for active luminal disease from M...

Full description

Saved in:
Bibliographic Details
Published in:The Journal of pediatrics 2022-01, Vol.240, p.150-157.e4
Main Authors: van Hoeve, Karen, Seyed Tabib, Nasim Sadat, Dreesen, Erwin, Tops, Sophie, Hoffman, Ilse, Gils, Ann, Ferrante, Marc, Vermeire, Séverine
Format: Article
Language:English
Subjects:
Adolescent
Child
Child, Preschool
children
Drug Monitoring
Endoscopy, Digestive System
Female
Follow-Up Studies
Gastrointestinal Agents - blood
Gastrointestinal Agents - therapeutic use
Humans
inflammatory bowel disease
Inflammatory Bowel Diseases - drug therapy
infliximab
Infliximab - blood
Infliximab - therapeutic use
Male
outcome
Prospective Studies
proteomics
Remission Induction
therapeutic drug monitoring
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To study infliximab (IFX) pharmacokinetics in children with inflammatory bowel disease (IBD) during induction therapy to predict outcome and explore if other covariates influenced outcome. All children with IBD starting IFX therapy (5 mg/kg at weeks 0, 2, 6, and 12) for active luminal disease from May 2017 to May 2019 were included and followed prospectively. Patients were sampled at multiple timepoints during induction (trough concentrations and peak concentration at weeks 0, 2, 6, and 12, and intermediate concentration at weeks 1-4). IFX concentrations and cumulative drug exposure were correlated with outcome at 6 months. Endoscopic remission was defined as Simple Endoscopic Score for Crohn's Disease of
ISSN:0022-3476
1097-6833
DOI:10.1016/j.jpeds.2021.08.079